What is Wegovy 1.7 mg FlexTouch?
Active Ingredient: Semaglutide.
Drug Class: GLP-1 (glucagon-like peptide-1) receptor agonist.
Form: Pre-filled injection pen (FlexTouch) — 3 mL of solution, delivering four 1.7 mg doses.
Use: Weight management in adults who are obese (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related health condition (e.g., high blood pressure, type 2 diabetes, or heart disease).
Additional Benefit: Helps reduce the risk of major cardiovascular events (heart attack, stroke) in certain high-risk individuals.
How Does Wegovy 1.7 mg Work?
Mimics the natural GLP-1 hormone, which helps regulate appetite.
Slows gastric emptying → makes you feel fuller for longer.
Acts on brain areas that reduce hunger and food cravings.
Mechanism: Mimics GLP-1 to slow stomach emptying, reduce hunger, increase satiety, and stabilize blood sugar, leading to lower calorie intake.
Effects: Builds gradually; once-weekly dosing maintains steady levels for sustained weight loss.
Semaglutide mimics GLP-1, a hormone that helps regulate appetite.
Wegovy 1.7 mg slows gastric emptying, making you feel fuller for longer.
Improves metabolic health, including better blood sugar control and potentially improved lipid profiles.
How to Use Wegovy 1.7 mg (Dosing and Administration)
Weight Management: Helps people with obesity or who are overweight (with related health conditions) lose weight and maintain weight loss.
Cardiovascular Risk Reduction: In certain patients (with high body weight and heart disease), it reduces the risk of heart attack, stroke, and other cardiovascular events.
Frequency: Once-weekly subcutaneous injection.
Injection Sites: Abdomen, thigh, or upper arm.
Dose Escalation: The 1.7 mg pen is typically used during a dose-up (titration) phase.
According to the UK summary, the escalation schedule is: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → then maintenance at 2.4 mg.
Preparing the Pen:
Attach a new needle before each injection.
Perform a “flow check” (first use of a new pen) to ensure the medicine comes out properly.
After injection, wait a few seconds (some instructions say ~6 seconds) to make sure the full dose is delivered.
Storage:
Store unopened pens in the fridge (2–8°C).
After first use, some sources allow storage below 30°C (check local guidance).
Side Effects
Common side effects may include:
Serious / Special Warnings:
Wegovy 1.7 mg is contraindicated if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2).
Use with caution if you have a history of pancreatitis or severe gastrointestinal disease. (General GLP-1 warning — check with your doctor.)
There may be a risk of gallbladder disease/gallstones due to weight loss.
People with type 2 diabetes, risk of hypoglycemia when using insulin or sulfonylureas.
Precautions & Things to Be Careful About
Hydration: Because GI side effects (nausea, vomiting, diarrhea) can lead to dehydration, especially in higher doses.
Kidney Health: Dehydration can worsen kidney function, so monitor if you have kidney issues.
Injection Technique: Rotate injection sites. Do not inject into damaged skin.
Gastroparesis: Not recommended if you have severe delayed stomach emptying.
Storage: Follow pen-specific instructions to maintain drug stability.
Missed Doses: If you miss a weekly dose, there’s guidance on when to take it again or skip; check with your healthcare provider.
October or leaflet.)
Advantages / Benefits
Very effective for sustained weight loss in obesity/overweight.
Helps reduce cardiovascular risk in certain overweight/obese individuals with heart disease.
Once-weekly injection → more convenient than daily medications.
Because it’s long-acting, fluctuations in effect are smoother.
Limitations / Things to Watch For
Gastrointestinal side effects are common, especially during dose escalation.
Cost: These pens can be expensive (depending on the country/insurance).
Not for everyone: People with certain medical histories (thyroid cancer, pancreatitis) may not be eligible.
Requires careful injection technique and storage.
Long-term maintenance (beyond weight loss) needs medical supervision.
Bottom Line
Wegovy 1.7 mg FlexTouch is an intermediate-dose, weekly injectable form of semaglutide used for weight management in people with obesity or overweight (with comorbidities).
Wegovy 1.7 mg helps reduce appetite and improve metabolic health, but comes with gastrointestinal side effects and requires dose escalation and lifestyle changes. It’s very effective when used under medical supervision.